U.S. research roundup: Capricor Therapeutics, Charles River Laboratories, General Mills

CAPR•2026-11-12

Analysts raised Capricor Therapeutics to buy and lifted Charles River Laboratories’ price target to $388 from $325, while cutting General Mills to neutral from overweight and lowering its target to $35 from $41.

U.S. research roundup: Capricor Therapeutics, Charles River Laboratories, General Mills

1. Analyst actions

Related News

SciBase announces Nevisense use in NIH-led study of environmental exposure effects on skin

China calls for efforts with US for early implementation of tariff-cut deal

EPR Properties prices $500.0 million convertible senior notes offering

HighPeak Energy Inc: Gerdes Energy Research raises to neutral from sell

General Mills: Piper Sandler cuts to neutral from overweight, lowers target price to $35 from $41